EXPOSURE-RESPONSE RELATIONSHIPS FOR THE EFFECT OF UPADACITINIB ON CLINICAL AND ENDOSCOPIC EFFICACY ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE – ANALYSIS OF CELEST STUDY

Mohamed-Eslam F. Mohamed  1     Ben Klünder  2     Ana P. Lacerda  3     Ahmed A. Othman  4    
1 AbbVie,Clinical Pharmacology and Pharmacometrics,North Chicago,United States of America
2 AbbVie Deutschland GmbH & Co. KG,Clinical Pharmacology and Pharmacometrics,Ludwigshafen am Rhein,Germany
3 AbbVie Inc.,Immunology Development,North Chicago,United States of America
4 AbbVie,Clinical Pharmacology and Pharmacometrics,North Chicago,U

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing